Want to see TSE:HEAL full AI Analyst Report?
HEAL Stock Chart & Stats
C$0.08
C$0.00(0.00%)
At close: 4:00 PM EDT
C$0.08
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.07 - C$0.14
Previous CloseN/A
Volume3.00K
Average Volume (3M)3.65K
Market Cap
C$5.19M
Enterprise ValueC$2.50M
Total Cash (Recent Filing)C$1.19M
Total Debt (Recent Filing)C$354.09K
Price to Earnings (P/E)―
Beta1.31
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding61,077,354
10 Day Avg. Volume5,146
30 Day Avg. Volume3,650
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.29
Price to Sales (P/S)0.00
P/FCF Ratio-5.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved 2025 Balance SheetThe shift to positive equity and modest debt in 2025 materially reduces short-term insolvency risk and improves financing optionality. This stronger capital structure can support R&D or operational steps without immediate emergency financing, a durable improvement for the next several quarters.
Rebuilding Asset BaseAn expanded asset base versus prior trough years signals restored operational capacity and potential collateral for creditors or partners. Over 2–6 months this supports executing development plans, attracting partners, and underpins longer-term recovery in business operations.
Reduced Cash Outflow TrendA demonstrable reduction in cash burn versus peak years suggests management is moderating spending or improving operational efficiency. While still negative, this trend extends runway and lowers the cadence of external funding needs, improving sustainability over the medium term.
Bears Say
No Recurring RevenueA sustained absence of recurring revenue indicates the company lacks a commercialized product or stable revenue streams, forcing reliance on financing. Over months this undermines prospects for self-sufficiency and constrains investments in growth or commercialization.
Persistent Negative Cash FlowContinuous negative operating and free cash flow signals ongoing cash burn that requires external capital. This structural dependency increases dilution risk, raises financing costs, and limits strategic flexibility over the coming quarters until cash generation turns positive.
Historical Equity VolatilityPrior periods of negative equity reflect episodes of financial distress that can impair credibility with lenders and partners. Even with recent improvement, this history can limit access to favorable financing and remains a structural headwind for rebuilding stable operations.
Restart Life Sciences News
HEAL FAQ
What was Restart Life Sciences’s price range in the past 12 months?
Restart Life Sciences lowest stock price was C$0.07 and its highest was C$0.14 in the past 12 months.
What is Restart Life Sciences’s market cap?
Restart Life Sciences’s market cap is C$5.19M.
When is Restart Life Sciences’s upcoming earnings report date?
Restart Life Sciences’s upcoming earnings report date is Aug 21, 2026 which is in 17 days.
How were Restart Life Sciences’s earnings last quarter?
Currently, no data Available
Is Restart Life Sciences overvalued?
According to Wall Street analysts Restart Life Sciences’s price is currently Overvalued.
Does Restart Life Sciences pay dividends?
Restart Life Sciences does not currently pay dividends.
What is Restart Life Sciences’s EPS estimate?
Restart Life Sciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Restart Life Sciences have?
Restart Life Sciences has 61,077,354 shares outstanding.
What happened to Restart Life Sciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Restart Life Sciences?
Currently, no hedge funds are holding shares in TSE:HEAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Restart Life Sciences
Operating internationally through its various subsidiaries, Restart Life Sciences Corp. functions as a biotechnology firm. Its core endeavors include the creation of natural therapeutic remedies tailored for individuals with autism spectrum disorder, the development of health-promoting foods designed for comprehensive mind and body wellness, and the execution of a psilocybin clinical trial aimed at fragile X syndrome. Founded in 2004 and based in Vancouver, Canada, the company adopted its current name in November 2024, having previously been known as Nova Mentis Life Science Corp.